ORACLE

Finished Formulations

The Research and Development operations for both generic and innovative formulations are supported by two advanced, autonomous laboratories, housed in a 1200 m2 building in Germany. These premises feature a GLP/GMP compliant environment, where lab-scale and pilot-scale development are conducted. Scaling-up is executed in collaboration with the Industrial Units following quality and process control strategies.

With the application of innovative techniques and advances technologies, Oracle aims to provide Life Cycle Management solutions to brand companies as well as to develop and establish new technology platforms and provide optimized pharmaceutical products to patients.

R&D / Active Pharmaceutical Ingredients

The APIs operations are supported by the API Research and Development Centre located in Germany.

Our lab features the most hi-tech instrumentation and equipment. This results in the development of high-quality products through innovating cost-effective processes, compliance with the standards of International Guidelines and Pharmacopoeias, as well as on-time delivery.

Our center's management system, structure and established partnerships with contract manufacturers offers:

Innovative, non-infringing, cost effective processes.

Analytical method development and validation.

Quality control of all stages of process (from raw material to final API).

Genotoxic evaluation and control of impurities.

Control of cost in all stages of process (raw materials, intermediates, manufacturing cost).

Pilot and commercial quantities of APIs.

“Innovation is the Translation of an Idea, the Creation of a Change”

At Oracle we are changing the perception of conventional medication, improving the effectiveness of drug therapy and enhancing patient compliance.

As a research-oriented company, we aim at the development and registration of novel technologies, high quality Active Pharmaceutical Ingredients and pharmaceutical products both in the field of generics and innovative formulations.

Our Performance

More than 100 products successfully developed and commercialized

Strong R&D pipeline of over 35 new products.

Success in product development, 95%.

First time Success in BE studies, 87%.

Successfully developed and applied technology platforms for oral, parenteral and ocular administration.

IP generation for more than 70% of our developments.

Our Team

Our Scientists are the most valuable asset, realizing company's dreams and ambitions.
Our R&D team consists of approximately 100 scientists from different nationalities.

ABOUT US